Effect of Rebound Exercise in Individuals With Type 2 Diabetes

Not Applicable

Completed

• Conditions: Type 2 Diabetes

• Registration Number: NCT02701569
• Lead Sponsor: University of KwaZulu

Brief Summary

The purpose of this study was to investigate the effect of rebound exercise (mini trampoline jumping) on metabolic outcomes and quality of life in patients with Type 2 Diabetes.

Detailed Description

The exercise involved jumping on the mini trampoline with feet slightly apart. Participants stood on the mid portion of the trampoline bed and made repeated up-and-down bouncy movements. Each foot strike equals one step or bounce. With each landing, the mat of the trampoline underwent deformation and the springs released the energy stored in them such that the participant was made to bounce off the mat. Exercise was administered for between 10 - 15 minutes after which a 5-minute period of rest was allowed. A heart rate monitor was used to guide the intensity of the exercise in the moderate range. Each participant accumulated between 20 and 30 minutes of rebound exercise (bouncing on a mini trampoline) per session, administered three times per week for 12 weeks. All data were captured at baseline and at the end of the 12-week intervention period.

Study Timeline

• Study Start: 2014-07
• Primary Completion: 2015-06
• Study Completion: 2015-06
• Status Verified: 2016-02
• Study First Submitted: 2016-02-17
• Study First Submitted QC: 2016-03-02
• Study First Posted: 2016-03-08
• Last Update Submitted: 2016-10-26
• Last Update Posted: 2016-10-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• 30- to 60-year-old male and female individuals;
• A diagnosis of type 2 diabetes ≤ 5 years;
• Attendance at the Diabetes Outpatient Clinics of Aminu Kano Teaching Hospital and Murtala Muhammad Specialist Hospital in Kano, Northwestern Nigeria;
• Self-ambulatory;
• An inactive lifestyle over the last year.

Exclusion Criteria

• A diagnosis of type 2 diabetes for more than 5 years;
• Hypertension (systolic and diastolic blood pressure more than 140 and 90 mmHg, respectively) or treatment for hypertension;
• Use of insulin therapy
• Lower limb weakness and/or deformities with loss of protective sensation in the feet;
• Back, shoulder or knee problems and/or joint instability;
• History of coronary artery disease, retinopathy and nephropathy;
• Myocardial infarction, cardiac or abdominal surgery within the previous 6 months;
• History of fractures of the spine, hip, knee and/or ankle joints.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Glycated hemoglobin	3 months	Glycated hemoglobin was assessed using the mini-column ion-exchange chromatographic method and expressed in percentage

Secondary Outcome Measures

Name	Time	Method
Height	3 months	Height in meters was determined using a stadiometer
Heart rate	3 months	Heart rate was measured in beats per minute using a calibrated electronic device
Respiratory rate	3 months	Respiratory rate (in cycles per minute) was measured by observing and counting the number of times the chest rose in one minute
Blood pressure	3 months	Blood pressure in millimeters of mercury (mmHg) was measured using a calibrated electronic device
Fasting plasma glucose	3 months	Fasting plasma glucose (in molar concentration) was measured by glucose oxidase assay using a glucose analyzer
Fasting insulin	3 months	Fasting insulin (in gravimetric unit) was determined using a commercially available ELISA human insulin kit
High-density lipoprotein cholesterol	3 months	High-density lipoprotein cholesterol (in molar concentration) was enzymatically determined using commercial kits
Total cholesterol	3 months	Total cholesterol (in molar concentration) was enzymatically determined using commercial kits
Triglycerides	3 months	Triglycerides (in molar concentration) were enzymatically determined using commercial kits
Low-density lipoprotein cholesterol	3 months	Low-density lipoprotein cholesterol (in molar concentration) was estimated using the Friedewald formula.
Quality of life	3 months	The short-form 36 health questionnaire was used to assess participants' quality of life and expressed in percentage
Body mass	3 months	Body mass in kilograms was determined using a calibrated weighing scale
Maximal oxygen consumption	3 months	Maximal oxygen consumption in milliliters per kilogram per minute (ml/kg/min) was obtained from exercise stress testing
Diabetes-related emotional distress as measured by the Problem Areas in Diabetes Scale	3 months	Diabetes-related emotional distress was expressed in percentage
Well-Being as measured by the World Health Organization-Well-Being Index	3 months	Participants' well-being was expressed in percentage
Treatment satisfaction as measured by the World Health Organization-Diabetes Treatment Satisfaction Questionnaire	3 months	Score ranges from 0 (very dissatisfied) to 36 (very satisfied)